Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Enlivex ( (ENLV) ) is now available.
Enlivex Therapeutics Ltd. announced on September 9, 2025, the issuance of an Israeli patent that extends intellectual property protection for its Allocetra™ treatment for osteoarthritis until at least 2040. This development follows positive results from a Phase IIa clinical trial, which demonstrated significant improvements in knee pain and function for patients with moderate-to-severe knee osteoarthritis. The patent strengthens Enlivex’s market position and suggests potential for similar patents in other major jurisdictions, offering assurance to stakeholders about the company’s future prospects in the osteoarthritis treatment market.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, which is crucial for immune system rebalancing and resolving life-threatening and debilitating conditions.
Average Trading Volume: 540,725
Technical Sentiment Signal: Sell
Current Market Cap: $25.29M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.